Company profile for EMERCell

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

EMERCell is developing a generic cell immunotherapy NK-based to be used in synergy with monoclonal antibodies (MAbs) to treat refractory patients in oncology. This new and innovative drug therapy called NK-001 consists of allogeneic Natural Killer (NK) cells which are produced ex vivo according to a patented process. NK lymphocytes present natural cytotoxicity and specific cytotoxicity in association with MAbs (Antibody-Depen...
EMERCell is developing a generic cell immunotherapy NK-based to be used in synergy with monoclonal antibodies (MAbs) to treat refractory patients in oncology. This new and innovative drug therapy called NK-001 consists of allogeneic Natural Killer (NK) cells which are produced ex vivo according to a patented process. NK lymphocytes present natural cytotoxicity and specific cytotoxicity in association with MAbs (Antibody-Dependent Cell Cytotoxicity (ADCC)) and are known for their natural immunology surveillance of cancers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
36 Chemin de l’hôpital 34270 St Mathieu de Tréviers
Telephone
Telephone
+(33) 6.14.77.39.21
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/onward-therapeutics-announces-impd-approval-for-its-subsidiary-emercell-to-start-clinical-investigation-of-allogeneic-nk-cell-therapy-ot-c001-in-combination-with-rituximab-302433928.html

PR NEWSWIRE
22 Apr 2025

https://www.contractpharma.com/contents/view_breaking-news/2022-10-03/emercell-and-cell-easy-sign-strategic-agreement-for-scale-up-manufacturing-of-nk-001/9769

CONTRACTPHARMA
03 Oct 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty